Volume 67, Issue 6 pp. 433-435
EDITORIAL

Hopes and concerns regarding the implementation of expanded access protocols in amyotrophic lateral sclerosis

Ikjae Lee MD

Corresponding Author

Ikjae Lee MD

Department of Neurology, Columbia University Irving Medical Center, New York, New York, USA

Correspondence

Ikjae Lee, Department of Neurology, Columbia University Irving Medical Center, 710 W 168th street, NI-3, New York, NY 10032.

Email: [email protected]

Search for more papers by this author
Zachary Simmons MD

Zachary Simmons MD

Department of Neurology, Penn State College of Medicine, Hershey, Pennsylvania, USA

Search for more papers by this author
First published: 30 March 2023
Citations: 1

CONFLICT OF INTEREST STATEMENT

Ikjae Lee: I have received research funding from the Myasthenia Gravis Foundation of America, American Academy of Neurology, CReATe consortium and American Brain Foundation. I am on the Scientific Advisory Committee for Alexion Pharmaceuticals and received honorarium. I am on the Independent Data Monitoring Committee for Regeneron Pharmaceuticals. I have received consulting fee from the Amylx pharmaceutical company. I have provided CME session on Spinal Muscular Atrophy and received honorarium from the Medscape.

Zachary Simmons has received consultation fees from Amylyx, Biogen, Clene, Corcept, Cytokinetics, and research support from Biosensics, MT Pharma and Sanofi.

The full text of this article hosted at iucr.org is unavailable due to technical difficulties.

click me